Exploring Lysophosphatidylcholine as a Biomarker in Ischemic Stroke: The Plasma–Brain Disjunction
Abstract
:1. Introduction
2. Results
2.1. Decreased Plasma Levels of LPC Exhibit an Inverse Correlation with Brain LPC Concentrations and Lesion Volume in Ischemic Stroke
2.2. Increased Brain LPC Levels Lead to Impaired Cerebral Blood Flow and a Decrease in Salvageable Tissue Following Ischemic Stroke
2.3. Plasma LPC Levels Are Inversely Correlated with Brain LPC Levels Following Ischemic Stroke
2.4. Both Plasma and Brain LPC Levels Are Strongly Correlated with Sensorimotor Dysfunction Following Ischemic Stroke
2.5. Both Plasma and Brain LPC Levels Show a Strong Correlation with Established Mechanistic Biomarkers in Ischemic Stroke
3. Discussion
4. Materials and Methods
4.1. Animals
4.2. Experimental Groups and Exclusion Criteria
4.3. Transient Middle Cerebral Artery Occlusion
4.4. Drug Administration
4.5. Laser Speckle Flowmetry
4.6. Neurobehavioral Assessments
4.6.1. Garcia Score
4.6.2. Proprioception
4.7. Sample Collection and Processing
4.8. TTC Staining and Lesion Assessment
4.9. LPC Analysis via HPLC-MS
4.10. Western Blotting
4.11. Statistical Analyses
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Herpich, F.; Rincon, F. Management of Acute Ischemic Stroke. Crit. Care Med. 2020, 48, 1654. [Google Scholar] [CrossRef] [PubMed]
- Kwakkel, G.; Veerbeek, J.M.; Harmeling-van der Wel, B.C.; van Wegen, E.; Kollen, B.J.; on behalf of the Early Prediction of functional Outcome after Stroke (EPOS) Investigators. Diagnostic Accuracy of the Barthel Index for Measuring Activities of Daily Living Outcome after Ischemic Hemispheric Stroke. Stroke 2011, 42, 342–346. [Google Scholar] [CrossRef] [PubMed]
- Fahey, M.; Crayton, E.; Wolfe, C.; Douiri, A. Clinical prediction models for mortality and functional outcome following ischemic stroke: A Syst. review and meta-analysis. PLoS ONE 2018, 13, e0185402. [Google Scholar] [CrossRef] [PubMed]
- Montellano, F.A.; Ungethüm, K.; Ramiro, L.; Nacu, A.; Hellwig, S.; Fluri, F.; Whiteley, W.N.; Bustamante, A.; Montaner, J.; Heuschmann, P.U. Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis. Stroke 2021, 52, 543–551. [Google Scholar] [CrossRef] [PubMed]
- Whiteley, W.; Chong, W.L.; Sengupta, A.; Sandercock, P. Blood Markers for the Prognosis of Ischemic Stroke. Stroke 2009, 40, e380–e389. [Google Scholar] [CrossRef]
- Huang, M.; Xu, S.; Zhou, M.; Luo, J.; Zha, F.; Shan, L.; Yang, Q.; Zhou, B.; Wang, Y. Lysophosphatidylcholines and Phosphatidylcholines as Biomarkers for Stroke Recovery. Front. Neurol 2022, 13, 1047101. Available online: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.1047101/full (accessed on 27 August 2024). [CrossRef]
- Huang, Y.; Wang, Z.; Huang, Z.X.; Liu, Z. Biomarkers and the outcomes of ischemic stroke. Front. Mol. Neurosci. 2023, 16, 1171101. [Google Scholar] [CrossRef]
- Dias, A.; Silva, L.; Moura, J.; Gabriel, D.; Maia, L.F. Fluid biomarkers in stroke: From animal models to clinical care. Acta Neurol. Scand. 2022, 146, 332–347. [Google Scholar] [CrossRef]
- Ponomarev, G.V.; Polyakova, A.V.; Prokhorova, M.V.; Voznjouk, I.A. Stroke biomarkers: Issues of diagnosis and medical rehabilitation. Phys. Rehabil. Med. Med. Rehabil. 2022, 4, 259–270. [Google Scholar] [CrossRef]
- Rahmig, J.; Chanpura, A.; Schultz, A.; Barone, F.C.; Gustafson, D.; Baird, A.E. Blood-Based Protein Biomarkers during the Acute ischemic Stroke Treatment Window: A Systematic Review. Front. Neurol 2024, 15, 1411307. Available online: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1411307/full (accessed on 27 August 2024). [CrossRef]
- di Biase, L.; Bonura, A.; Pecoraro, P.M.; Carbone, S.P.; Di Lazzaro, V. Unlocking the Potential of Stroke Blood Biomarkers: Early Diagnosis, Ischemic vs. Haemorrhagic Differentiation and Haemorrhagic Transformation Risk: A Comprehensive Review. Int. J. Mol. Sci. 2023, 24, 11545. [Google Scholar] [CrossRef] [PubMed]
- Florijn, B.W.; van der Bent, M.L.; Nguyen, T.M.T.; Quax, P.H.A.; Wermer, M.J.H.; Yaël Nossent, A.; Kruyt, N.D. Non-coding RNAs versus protein biomarkers to diagnose and differentiate acute stroke: Systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 2023, 32, 107388. [Google Scholar] [CrossRef] [PubMed]
- Bernoud-Hubac, N.; Lo Van, A.; Lazar, A.N.; Lagarde, M. Ischemic Brain Injury: Involvement of Lipids in the Pathophysiology of Stroke and Therapeutic Strategies. Antioxidants 2024, 13, 634. [Google Scholar] [CrossRef] [PubMed]
- Andone, S.; Farczádi, L.; Imre, S.; Bălașa, R. Fatty Acids and Lipid Paradox-Neuroprotective Biomarkers in Ischemic Stroke. Int. J. Mol. Sci. 2022, 23, 10810. [Google Scholar] [CrossRef] [PubMed]
- Chen, K.N.; He, L.; Zhong, L.M.; Ran, Y.Q.; Liu, Y. Meta-Analysis of Dyslipidemia Management for the Prevention of Ischemic Stroke Recurrence in China. Front. Neurol. 2020, 11, 483570. [Google Scholar] [CrossRef]
- Lucke-Wold, B.P.; Turner, R.C.; Lucke-Wold, A.N.; Rosen, C.L.; Huber, J.D. Age and the metabolic syndrome as risk factors for ischemic stroke: Improving preclinical models of ischemic stroke. Yale J. Biol. Med. 2012, 85, 523–539. [Google Scholar]
- Boehme, A.K.; Esenwa, C.; Elkind, M.S.V. Stroke Risk Factors, Genetics, and Prevention. Circ. Res. 2017, 120, 472–495. [Google Scholar] [CrossRef]
- Ma, Y.; Chen, Z.; He, Q.; Guo, Z.N.; Yang, Y.; Liu, F.; Li, F.; Luo, Q.; Chang, J. Spatiotemporal lipidomics reveals key features of brain lipid dynamic changes after cerebral ischemia and reperfusion therapy. Pharmacol. Res. 2022, 185, 106482. [Google Scholar] [CrossRef]
- Golovko, S.A.; Golovko, M.Y. Plasma Unesterified Fatty-Acid Profile Is Dramatically and Acutely Changed under Ischemic Stroke in the Mouse Model. Lipids 2018, 53, 641–645. [Google Scholar] [CrossRef]
- Zeiger, S.L.H.; Musiek, E.S.; Zanoni, G.; Vidari, G.; Morrow, J.D.; Milne, G.J.; McLaughlin, B. Neurotoxic lipid peroxidation species formed by ischemic stroke increase injury. Free. Radic. Biol. Med. 2009, 47, 1422–1431. [Google Scholar] [CrossRef]
- Mulder, I.A.; Ogrinc Potočnik, N.; Broos, L.A.M.; Prop, A.; Wermer, M.J.H.; Heeren, R.M.A.; van den Maagdenberg, A.M.J.M. Distinguishing core from penumbra by lipid profiles using Mass Spectrometry Imaging in a transgenic mouse model of ischemic stroke. Sci. Rep. 2019, 9, 1090. [Google Scholar] [CrossRef] [PubMed]
- Zheng, L.; Xie, C.; Zheng, J.; Dong, Q.; Si, T.; Zhang, J.; Hou, S.T. An imbalanced ratio between PC (16:0/16:0) and LPC (16:0) revealed by lipidomics supports the role of the Lands cycle in ischemic brain injury. J. Biol. Chem. 2021, 296, 100151. [Google Scholar] [CrossRef] [PubMed]
- Hoda, M.N.; Singh, I.; Singh, A.K.; Khan, M. Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat. J. Neuroinflamm. 2009, 6, 21. [Google Scholar] [CrossRef] [PubMed]
- Achón Buil, B.; Rust, R. Preserving stroke penumbra by targeting lipid signalling. J. Cereb. Blood Flow. Metab. 2023, 43, 167–169. [Google Scholar] [CrossRef]
- Wang, C.; Zhang, J.; Tang, J.; Li, Y.Y.; Gu, Y.; Yu, Y.; Xiong, J.; Zhao, X.; Zhang, Z.; Li, T.T.; et al. Lysophosphatidic acid induces neuronal cell death via activation of asparagine endopeptidase in cerebral ischemia-reperfusion injury. Exp. Neurol. 2018, 306, 1–9. [Google Scholar] [CrossRef]
- Nakamura, A.; Otani, K.; Shichita, T. Lipid mediators and sterile inflammation in ischemic stroke. Int. Immunol. 2020, 32, 719–725. [Google Scholar] [CrossRef] [PubMed]
- Chomova, M.; Zitnanova, I. Look into brain energy crisis and membrane pathophysiology in ischemia and reperfusion. Stress 2016, 19, 341–348. [Google Scholar] [CrossRef]
- Liu, M.; Zhou, K.; Li, H.; Dong, X.; Tan, G.; Chai, Y.; Wang, W.; Bi, X. Potential of serum metabolites for diagnosing post-stroke cognitive impairment. Mol. BioSyst. 2015, 11, 3287–3296. [Google Scholar] [CrossRef]
- Mavroudakis, L.; Stevens, S.L.; Duncan, K.D.; Stenzel-Poore, M.P.; Laskin, J.; Lanekoff, I. CpG preconditioning reduces accumulation of lysophosphatidylcholine in ischemic brain tissue after middle cerebral artery occlusion. Anal. Bioanal. Chem. 2021, 413, 2735–2745. [Google Scholar] [CrossRef]
- Zhang, H.; Guo, W.; Li, X.; Xie, S.; Liu, Y.; Chen, G.; Wang, Y.; Xu, Y. Supplementation with Tribulus Terrestris Extract Exhibits Protective Effects on MCAO Rats via Modulating Inflammation-Related Metabolic and Signaling Pathways. ACS Omega 2023, 8, 2306–2314. [Google Scholar] [CrossRef]
- Sabogal-Guáqueta, A.M.; Posada-Duque, R.; Cortes, N.C.; Arias-Londoño, J.D.; Cardona-Gómez, G.P. Changes in the hippocampal and peripheral phospholipid profiles are associated with neurodegeneration hallmarks in a long-term global cerebral ischemia model: Attenuation by Linalool. Neuropharmacology 2018, 135, 555–571. [Google Scholar] [CrossRef] [PubMed]
- Wu, H.; Liu, H.; Zuo, F.; Zhang, L. Adenoviruses-mediated RNA interference targeting cytosolic phospholipase A2α attenuates focal ischemic brain damage in mice. Mol. Med. Rep. 2018, 17, 5601–5610. [Google Scholar] [CrossRef] [PubMed]
- Liu, P.; Zhu, W.; Chen, C.; Yan, B.; Zhu, L.; Chen, X.; Peng, C. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 2020, 247, 117443. [Google Scholar] [CrossRef]
- Law, S.H.; Chan, M.L.; Marathe, G.K.; Parveen, F.; Chen, C.H.; Ke, L.Y. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. Int. J. Mol. Sci. 2019, 20, 1149. [Google Scholar] [CrossRef]
- Ion, A.; Stafie, C.; Mitu, O.; Ciobanu, C.E.; Halitchi, D.I.; Costache, A.D.; Bobric, C.; Troase, R.; Mitu, I.; Huzum, B.; et al. Biomarkers Utility: At the Borderline between Cardiology and Neurology. J. Cardiovasc. Dev. Dis. 2021, 8, 139. [Google Scholar] [CrossRef]
- Shao, Y.; Nanayakkara, G.; Cheng, J.; Cueto, R.; Yang, W.Y.; Park, J.Y.; Wang, H.; Yang, X. Lysophospholipids and Their Receptors Serve as Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury. Antioxid. Redox Signal. 2018, 28, 973–986. [Google Scholar] [CrossRef]
- Zhong, C.; Zhu, Z.; Wang, A.; Xu, T.; Bu, X.; Peng, H.; Yang, J.; Han, L.; Chan, J.; Xu, T.; et al. Multiple biomarkers covering distinct pathways for predicting outcomes after ischemic stroke. Neurology 2019, 92, e295–e304. [Google Scholar] [CrossRef] [PubMed]
- Dong, X.; Song, Y.N.; Liu, W.G.; Guo, X.L. MMP-9, a Potential Target for Cerebral Ischemic Treatment. Curr. Neuropharmacol. 2009, 7, 269–275. [Google Scholar] [CrossRef]
- Wang, Y.C.; Lu, Y.B.; Huang, X.L.; Lao, Y.F.; Zhang, L.; Yang, J.; Shi, M.; Ma, H.L.; Pan, Y.W.; Zhang, Y.N. Myeloperoxidase: A new target for the treatment of stroke? Neural Regen. Res. 2022, 17, 1711. [Google Scholar]
- Cojocaru, I.M.; Cojocaru, M.; Iliescu, I.; Botnaru, L.; Gurban, C.V.; Sfrijan, F.; Tanasescu, R. Plasma myeloperoxidase levels in patients with acute ischemic stroke. Rom. J. Intern. Med. 2010, 48, 101–104. [Google Scholar]
- Glushakova, O.Y.; Glushakov, A.A.; Wijesinghe, D.S.; Valadka, A.B.; Hayes, R.L.; Glushakov, A.V. Prospective clinical biomarkers of caspase-mediated apoptosis associated with neuronal and neurovascular damage following stroke and other severe brain injuries: Implications for chronic neurodegeneration. Brain Circ. 2017, 3, 87. [Google Scholar] [CrossRef] [PubMed]
- Leontyev, D.; Pulliam, A.N.; Ma, X.; Gaul, D.A.; LaPlaca, M.C.; Fernández, F.M. Spatial Lipidomics Maps Brain Alterations Associated with Mild Traumatic Brain Injury. Front. Chem 2024, 12, 1394064. Available online: https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2024.1394064/full (accessed on 27 August 2024). [CrossRef] [PubMed]
- Gusdon, A.M.; Savarraj, J.P.; Redell, J.B.; Paz, A.; Hinds, S.; Burkett, A.; Torres, G.; Ren, X.; Badjatia, N.; Hergenroeder, G.W.; et al. Lysophospholipids Are Associated With Outcomes in Hospitalized Patients With Mild Traumatic Brain Injury. J. Neurotrauma 2024, 41, 59–72. [Google Scholar] [CrossRef] [PubMed]
- Thomas, I.; Dickens, A.M.; Posti, J.P.; Czeiter, E.; Duberg, D.; Sinioja, T.; Kråkström, M.; Retel Helmrich, I.R.A.; Wang, K.K.W.; Maas, A.I.R.; et al. Serum metabolome associated with severity of acute traumatic brain injury. Nat. Commun. 2022, 13, 2545. [Google Scholar] [CrossRef] [PubMed]
- Sabogal-Guáqueta, A.M.; Villamil-Ortiz, J.G.; Arias-Londoño, J.D.; Cardona-Gómez, G.P. Inverse Phosphatidylcholine/Phosphatidylinositol Levels as Peripheral Biomarkers and Phosphatidylcholine/Lysophosphatidylethanolamine-Phosphatidylserine as Hippocampal Indicator of Postischemic Cognitive Impairment in Rats. Front. Neurosci 2018, 12, 989. Available online: https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00989/full (accessed on 27 August 2024). [CrossRef]
- Mehta, S.L.; Chelluboina, B.; Morris-Blanco, K.C.; Bathula, S.; Jeong, S.; Arruri, V.; Davis, C.K.; Vemuganti, R. Post-stroke brain can be protected by modulating the lncRNA FosDT. J. Cereb. Blood Flow Metab. 2024, 44, 239–251. [Google Scholar] [CrossRef]
- Davaanyam, D.; Lee, H.; Seol, S.I.; Oh, S.A.; Kim, S.W.; Lee, J.K. HMGB1 induces hepcidin upregulation in astrocytes and causes an acute iron surge and subsequent ferroptosis in the postischemic brain. Exp. Mol. Med. 2023, 55, 2402–2416. [Google Scholar] [CrossRef]
- Gryglewski, R.J.; Nowak, S.; Kostka-Trabka, E.; Kusmiderski, J.; Dembinska-Kiec, A.; Bieron, K.; Basista, M.; Blaszczyk, B. Treatment of ischaemic stroke with prostacyclin. Stroke 1983, 14, 197–202. [Google Scholar] [CrossRef]
- Stein, R.W.; Papp, A.C.; Weiner, W.J.; Wu, K.K. Reduction of serum prostacyclin stability in ischemic stroke. Stroke 1985, 16, 16–18. [Google Scholar] [CrossRef]
- Jové, M.; Mauri-Capdevila, G.; Suárez, I.; Cambray, S.; Sanahuja, J.; Quílez, A.; Farré, J.; Benabdelhak, I.; Pamplona, R.; Portero-Otín, M.; et al. Metabolomics predicts stroke recurrence after transient ischemic attack. Neurology 2015, 84, 36–45. [Google Scholar] [CrossRef]
- Nishikimi, M.; Yagi, T.; Shoaib, M.; Takegawa, R.; Rasul, R.; Hayashida, K.; Okuma, Y.; Yin, T.; Choudhary, R.C.; Becker, L.B.; et al. Phospholipid Screening Postcardiac Arrest Detects Decreased Plasma Lysophosphatidylcholine: Supplementation as a New Therapeutic Approach. Crit. Care Med. 2022, 50, e199. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Lampe, J.W.; Yin, T.; Shinozaki, K.; Becker, L.B. Phospholipid alterations in the brain and heart in a rat model of asphyxia-induced cardiac arrest and cardiopulmonary bypass resuscitation. Mol. Cell Biochem. 2015, 408, 273–281. [Google Scholar] [CrossRef]
- Brindley, D.N. Hepatic secretion of lysophosphatidylcholine: A novel transport system for polyunsaturated fatty acids and choline. J. Nutr. Biochem. 1993, 4, 442–449. [Google Scholar] [CrossRef]
- Scagnelli, G.P.; Cooper, P.S.; VandenBroek, J.M.; Berman, W.F.; Schwartz, C.C. Plasma 1-palmitoyl-2-linoleoyl phosphatidylcholine. Evidence for extensive phospholipase A1 hydrolysis and hepatic metabolism of the products. J. Biol. Chem. 1991, 266, 18002–18011. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Han, Z.; Wang, R.; Fan, J.; Zheng, Y.; Huang, Y.; Yang, Z.; Yan, F.; Liu, P.; Zhao, H.; et al. Association of admission neutrophil serine proteinases levels with the outcomes of acute ischemic stroke: A prospective cohort study. J. Neuroinflamm. 2023, 20, 70. [Google Scholar] [CrossRef]
- Ismaeel, S.; Qadri, A. Lysophosphatidylcholine activates caspase-1 by bringing about release of ATP and sensitization of purinergic receptor. J. Immunol. 2019, 202 (Suppl. S1), 63.5. [Google Scholar] [CrossRef]
- Kaczmarek, A.; Vandenabeele, P.; Krysko, D.V. Necroptosis: The Release of Damage-Associated Molecular Patterns and Its Physiological Relevance. Immunity 2013, 38, 209–223. [Google Scholar] [CrossRef]
- O’Donnell, V.B. New appreciation for an old pathway: The Lands Cycle moves into new arenas in health and disease. Biochem. Soc. Trans. 2022, 50, 1–11. [Google Scholar] [CrossRef]
- Semba, R.D. Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease. Adv. Nutr. 2020, 11, 760–772. [Google Scholar] [CrossRef]
- McNamara, R.K.; Carlson, S.E. Role of omega-3 fatty acids in brain development and function: Potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot. Essent. Fat. Acids 2006, 75, 329–349. [Google Scholar] [CrossRef]
- Rioux, F.M.; Innis, S.M. Oleic Acid (18:1) in Plasma, Liver and Brain Myelin Lipid of Piglets Fed from Birth with Formulas Differing in 18:1 Content 12. J. Nutr. 1992, 122, 1521–1528. [Google Scholar] [CrossRef] [PubMed]
- Ojala, P.J.; Hirvonen, T.E.; Hermansson, M.; Somerharju, P.; Parkkinen, J. Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J. Leukoc. Biol. 2007, 82, 1501–1509. [Google Scholar] [CrossRef]
- Nishikimi, M.; Shoaib, M.; Choudhary, R.C.; Aoki, T.; Miyara, S.J.; Yagi, T.; Hayashida, K.; Takegawa, R.; Tin, T.; Becker, L.B.; et al. Preserving Brain LPC-DHA by Plasma Supplementation Attenuates Brain Injury after Cardiac Arrest. Ann. Neurol. 2022, 91, 389–403. [Google Scholar] [CrossRef]
- Wang, X.; Zhang, L.; Sun, W.; Pei, L.L.; Tian, M.; Liang, J.; Liu, X.; Zhang, R.; Fang, H.; Wu, J.; et al. Changes of Metabolites in Acute Ischemic Stroke and Its Subtypes. Front. Neurosci. 2021, 14, 580929. [Google Scholar] [CrossRef]
- Song, J.; Kim, Y.S.; Lee, D.H.; Lee, S.H.; Park, H.J.; Lee, D.; Kim, H. Neuroprotective effects of oleic acid in rodent models of cerebral ischaemia. Sci. Rep. 2019, 9, 10732. [Google Scholar] [CrossRef]
- Hara, Y.; Kusumi, Y.; Mitsumata, M.; Li, X.K.; Fujino, M. Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat. J. Thromb. Thrombolysis 2008, 26, 113–118. [Google Scholar] [CrossRef] [PubMed]
- Asaoka, Y.; Oka, M.; Yoshida, K.; Sasaki, Y.; Nishizuka, Y. Role of lysophosphatidylcholine in T-lymphocyte activation: Involvement of phospholipase A2 in signal transduction through protein kinase C. Proc. Natl. Acad. Sci. USA 1992, 89, 6447–6451. [Google Scholar] [CrossRef] [PubMed]
- Kollikowski, A.M.; Pham, M.; März, A.G.; Feick, J.; Vogt, M.L.; Xiong, Y.; Strinitz, M.; Vollmuth, C.; Essig, F.; Neugebauer, H.; et al. MMP-9 release into collateral blood vessels before endovascular thrombectomy to assess the risk of major intracerebral haemorrhages and poor outcome for acute ischaemic stroke: A proof-of-concept study. eBioMedicine 2024, 103, 105095. [Google Scholar] [CrossRef]
- Pham, L.D.D.; Hayakawa, K.; Seo, J.H.; Nguyen, M.N.; Som, A.T.; Lee, B.J.; Guo, S.; Kim, K.W.; Lo, E.H.; Arai, K. Crosstalk between oligodendrocytes and cerebral endothelium contributes to vascular remodeling after white matter injury. Glia 2012, 60, 875–881. [Google Scholar] [CrossRef]
- Mamytov, M.; Mamytova, E.; Toktomametova, A.; Miklukhin, D.; Vityala, Y.; Tagaev, T.; Kalikiri, S.; Kanteti, K.P. Expression of autophagy and apoptosis biomarkers in patients with acute ischemic stroke. Biomedicine 2022, 42, 988–991. [Google Scholar] [CrossRef]
- Radak, D.; Katsiki, N.; Resanovic, I.; Jovanovic, A.; Sudar-Milovanovic, E.; Zafirovic, S.; Mousa, S.A.; Isenovic, E.R. Apoptosis and Acute Brain Ischemia in Ischemic Stroke. Curr. Vasc. Pharmacol. 2017, 15, 115–122. [Google Scholar] [CrossRef] [PubMed]
- Song, J.; Liu, K.; Yi, J.; Zhu, D.; Liu, G.; Liu, B. Luteolin Inhibits Lysophosphatidylcholine-Induced Apoptosis in Endothelial Cells by a Calcium/Mithocondrion/Caspases-Dependent Pathway. Planta Medica 2009, 76, 433–438. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.M.; Hsu, J.H.; Liou, S.F.; Chen, T.J.; Chen, L.Y.; Chiu, C.C.; Yeh, J.L. Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways. BMC Complement. Altern. Med. 2014, 14, 233. [Google Scholar] [CrossRef] [PubMed]
- Riederer, M.; Ojala, P.J.; Hrzenjak, A.; Graier, W.F.; Malli, R.; Tritscher, M.; Hermansson, M.; Watzer, B.; Schweer, H.; Desoye, G.; et al. Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production [S]. J. Lipid Res. 2010, 51, 2957–2966. [Google Scholar] [CrossRef] [PubMed]
- Pluta, R. Complete Cerebral Ischemia, Prostacyclin Deficiency, and Therapeutic Possibilities. In Brain Edema IX; Ito, U., Baethmann, A., Hossmann, K.A., Kuroiwa, T., Marmarou, A., Reulen, H.J., Takakura, K., Eds.; Springer: Vienna, Austria, 1994; pp. 303–306. [Google Scholar]
- Jayaraj, R.L.; Azimullah, S.; Beiram, R.; Jalal, F.Y.; Rosenberg, G.A. Neuroinflammation: Friend and foe for ischemic stroke. J. Neuroinflamm. 2019, 16, 142. [Google Scholar] [CrossRef]
- Battey, T.W.K.; Karki, M.; Singhal, A.B.; Wu, O.; Sadaghiani, S.; Campbell, B.C.V.; Davis, S.M.; Donnan, G.A.; Sheth, K.N.; Kimberly, W.T. Brain edema predicts outcome after nonlacunar ischemic stroke. Stroke 2014, 45, 3643–3648. [Google Scholar] [CrossRef]
- Jin, R.; Yang, G.; Li, G. Inflammatory mechanisms in ischemic stroke: Role of inflammatory cells. J. Leukoc. Biol. 2010, 87, 779–789. [Google Scholar] [CrossRef]
- Sun, H.; Zhao, J.; Zhong, D.; Li, G. Potential serum biomarkers and metabonomic profiling of serum in ischemic stroke patients using UPLC/Q-TOF MS/MS. PLoS ONE 2017, 12, e0189009. [Google Scholar] [CrossRef]
- Lee, E.J.; Kim, D.J.; Kang, D.W.; Yang, W.; Jeong, H.Y.; Kim, J.M.; Ko, S.B.; Lee, S.H.; Yoon, B.W.; Cho, J.Y.; et al. Targeted Metabolomic Biomarkers for Stroke Subtyping. Transl. Stroke Res. 2024, 15, 422–432. [Google Scholar] [CrossRef]
- Liu, S.; Levine, S.R.; Winn, H.R. Targeting ischemic penumbra: Part I—From pathophysiology to therapeutic strategy. J. Exp. Stroke Transl. Med. 2010, 3, 47–55. [Google Scholar] [CrossRef]
- Sommer, C.J. Ischemic stroke: Experimental models and reality. Acta Neuropathol. 2017, 133, 245–261. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Turpin, J.; Wadolowski, S.; Tambo, W.; Kim, D.; Al Abed, Y.; Sciubba, D.M.; Becker, L.B.; Ledoux, D.; Kim, J.; Powell, K.; et al. Exploring Lysophosphatidylcholine as a Biomarker in Ischemic Stroke: The Plasma–Brain Disjunction. Int. J. Mol. Sci. 2024, 25, 10649. https://doi.org/10.3390/ijms251910649
Turpin J, Wadolowski S, Tambo W, Kim D, Al Abed Y, Sciubba DM, Becker LB, Ledoux D, Kim J, Powell K, et al. Exploring Lysophosphatidylcholine as a Biomarker in Ischemic Stroke: The Plasma–Brain Disjunction. International Journal of Molecular Sciences. 2024; 25(19):10649. https://doi.org/10.3390/ijms251910649
Chicago/Turabian StyleTurpin, Justin, Steven Wadolowski, Willians Tambo, Daniel Kim, Yousef Al Abed, Daniel M. Sciubba, Lance B. Becker, David Ledoux, Junhwan Kim, Keren Powell, and et al. 2024. "Exploring Lysophosphatidylcholine as a Biomarker in Ischemic Stroke: The Plasma–Brain Disjunction" International Journal of Molecular Sciences 25, no. 19: 10649. https://doi.org/10.3390/ijms251910649